@DmitriMA and
@1ronnie - about RPRX: (Royalty Pharma: a U.S.A. stock dealing in financing medical research and buying patents, with the ensuing royalties, which they already receive from existing pharmaceuticals and specialising in difficult and expensive-to-treat, also aging-related illnesses, like cancer etc. - that's how I understand their business model - please amend, if incorrect!!)
I managed to subscribe to their newsletter and today got their first email detailing what it is that they are doing.
They - collectively - must have access to a lot of funds, apart from share holders, because the way I see it, they talk about funding research into new treatments as well - of course if they have been going for a while, so there must already be a royalty payment flow.
In Australia it's pretty easy to get a complete biography of a company from the very beginning (I usually do it on commsec), is there a way to do this in the U.S.?
Here is an excerpt from today's newsletter,
"AdvisorsGoodwin Procter LLP and Fenwick & West LLP acted as legal advisors to
Royalty Pharma.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a
leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
Royalty Pharma
has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies.
Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly –
directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when
it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes
royalties on more than 35 commercial products, including Vertex’s Trikafta, Kalydeco, Orkambi and Symdeko, Biogen’s Tysabri, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, GSK’s Trelegy, Novartis’ Promacta, Pfizer’s Nurtec ODT, Johnson & Johnson’s Tremfya, Roche’s Evrysdi, Gilead’s Trodelvy, and 17 development-stage product candidates."
They seem to be a relatively young team, still active in their various specialties . . . I can't quite get my head around how this 'brave new world' functions . . . might buy a few, just in case!! But will check out the meds first.
Is there somewhere one can get a lowdown on this company? ir presentation is pretty glib.
Take care
Taurisk
